{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:05:29Z","timestamp":1787227529598,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The global rise in extended\u2010spectrum \u03b2\u2010lactamase\u2010producing Enterobacterales (ESBL\u2010E) has created significant challenges in the management of severe infections, including bacteremia. Ertapenem, a once\u2010daily carbapenem with high protein\u2010binding affinity (85%\u201095%), is an ideal option for ESBL\u2010E because of its spectrum and dosing convenience. However, hypoalbuminemia, a common condition in critically ill patients that is independently associated with poor outcomes, raises concerns about altered pharmacokinetics, specifically increased free drug fractions, enhanced clearance, and shortened half\u2010life. These pharmacokinetic changes have been hypothesized to lead to suboptimal drug levels and treatment failure, although clinical evidence remains inconsistent. This narrative review examines ertapenem's pharmacokinetic and pharmacodynamic changes in patients with hypoalbuminemia, focusing on its clinical implications. While some studies have reported suboptimal outcomes in critically ill patients, others have demonstrated comparable efficacy to broader spectrum carbapenems when minimum inhibitory concentration values are favorable, and source control is achieved. These findings challenge the concerns raised in the 2024 Infectious Diseases Society of America Gram\u2010negative resistance guidance, which cautions against ertapenem use in patients with hypoalbuminemia. Rather than universally avoiding ertapenem, clinicians should prioritize individualized decision making based on patient\u2010specific factors. Further research is warranted to optimize dosing strategies. However, current data suggest that ertapenem remains a viable and effective option in this high\u2010risk population when used judiciously.<\/jats:p>","DOI":"10.1002\/jcph.70011","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:35:28Z","timestamp":1740029728000},"page":"961-969","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ertapenem in the Context of Hypoalbuminemia: Implications for Critically Ill Patients"],"prefix":"10.1002","volume":"65","author":[{"given":"Micaela Elene","family":"Seazzu","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of New Mexico Health Sciences Center  Albuquerque NM USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5402-0240","authenticated-orcid":false,"given":"M. Gabriela","family":"Cabanilla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of New Mexico Health Sciences Center  Albuquerque NM USA"},{"name":"Department of Internal Medicine, Division of Infectious Diseases University of New Mexico Health Sciences Center  Albuquerque NM USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit395"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-014-0541-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0413-2020"},{"key":"e_1_2_10_8_1","unstructured":"Merck & Co. Inc. (2020).INVANZ\u00ae (ertapenem for injection) prescribing information.https:\/\/www.accessdata.fda.gov"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S102819"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.07.020"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094496"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.SLA.0000055547.93484.87"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197608)38:2<854::AID-CNCR2820380232>3.0.CO;2-H"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-012-0802-0"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539220-000000000-00000"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168411"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku226"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.10.005"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad079"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl485"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.12.008"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.08.003"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231205219"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00287-22"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.654"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04005.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad102"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00066-20"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01663-23"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.05.018"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0549-x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010026"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035023"},{"issue":"4","key":"e_1_2_10_34_1","article-title":"The relationship between serum albumin levels and sepsis in patients admitted to a tertiary care center in India","volume":"16","author":"Kumar HG","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_10_35_1","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2024"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac209"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107352"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-020-00212-x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9492-y"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01403-1"},{"issue":"6","key":"e_1_2_10_41_1","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00367-24","article-title":"Possibility of hypoalbuminemia itself as a risk for clinical failure","volume":"68","author":"Sumiyoshi S","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614554919"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2023.06.003"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00231-7"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.06.008"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2007.12.008"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.06.015"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:04:32Z","timestamp":1753895072000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/jcph.70011"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70011","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}